Help & Support

BPL, the maker of COAGADEX, has been producing plasma-based products for more than 60 years.

We have several resources that can answer questions and provide support…all you need to do is ask!

Copay Assistance

If you have a prescription for COAGADEX and are having difficulty paying for your medication, BPL may be able to help.

  • The COAGADEX Copay Support Program will provide up to $12,000 per calendar year to cover out-of-pocket expenses for your COAGADEX prescription.
  • Some restrictions apply. To see if you qualify, visit


BPL is committed to helping patients find answers to their questions about COAGADEX. This includes helping patients with:

  • Copay assistance
  • Issues with insurance coverage
  • Prior authorizations and appeals
  • Other questions related to COAGADEX
Call 844-4BPLUSA

Talking with Your Doctor About COAGADEX

If you want to talk to your healthcare provider about COAGADEX, the COAGADEX Guide can help. Read the information on the front and answer the questions on the back. Then show the sheet to your healthcare provider and tell them that you’d like to talk about whether COAGADEX is right for you.

Other Resources & Links

For additional information about factor X deficiency and upcoming events in the bleeding disorder community, visit these resources.

You can also get help and support at your local hemophilia treatment center (HTC). In fact, people with bleeding disorders should visit their HTC at least once a year for a comprehensive clinic visit. To find an HTC near you, talk to your healthcare provider or visit the CDC web site.

Indications and Usage for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency

Limitation of Use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.

Contraindication for COAGADEX

COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.

Important Safety Information for COAGADEX

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.